CDK12

The CDK12 gene plays a fundamental role in maintaining the integrity of our DNA and ensuring proper cell division. However, when mutations occur in this gene, it can disrupt these essential processes, potentially leading to the development of cancer. Let‘s delve into the world of the CDK12 gene, its connection to cancer, and the exciting advancements in targeted therapies.

What is the CDK12 Gene?

CDK12 stands for Cyclin-Dependent Kinase 12. This gene provides instructions for making a protein that acts as a kinase, an enzyme that modifies other proteins by adding phosphate groups. CDK12‘s primary function is to regulate DNA repair and transcription, the process of converting DNA into RNA.

CDK12 Mutations and Cancer Risk

Mutations in the CDK12 gene can impair its ability to regulate DNA repair and transcription. This can lead to genetic instability, where cells accumulate DNA damage and errors, ultimately increasing the risk of cancer development.

Statistics:

• Ovarian Cancer: CDK12 mutations are most commonly found in ovarian cancer, particularly in high-grade serous ovarian cancer (HGSOC). Studies suggest that 10-20% of HGSOC cases harbor CDK12 mutations.
• Prostate Cancer: CDK12 mutations are also detected in a subset of prostate cancers, particularly those with aggressive features.
• Other Cancers: Emerging research suggests that CDK12 mutations may play a role in other cancers, including breast, endometrial, and bladder cancers.

Who Should Consider Genetic Testing?

Genetic testing for CDK12 mutations may be recommended for individuals with:

• A personal or family history of ovarian or prostate cancer
• A diagnosis of high-grade serous ovarian cancer
• A desire to explore potential targeted therapy options